In the first and fifth paragraphs of release dated Aug. 14, 2024, investor company name should read: Merck KGaA, Darmstadt, ...

TELUS Digital Experience (TELUS Digital) officially launched its global rebrand today, transitioning from TELUS International to TELUS Digital. The new name reflects the company's commitment to ...

UK government’s £500m taxpayer-backed deal for steelworks secures long-term future of Port Talbot but unable to secure guarantees to save 2,500 jobs ...

BERKELEY, Calif., September 03, 2024--(BUSINESS WIRE)--In the first and fifth paragraphs of release dated Aug. 14, 2024, investor company name should read: Merck KGaA, Darmstadt, Germany (instead ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

In addition to Truist Financial, Merck & Company also received a Buy from Goldman Sachs’s Chris Shibutani in a report issued today. However, on August 29, Wells Fargo maintained a Hold rating on ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...